Skip to main content
S&P 5007,650.50+0.17%DOW51,682.64-0.18%NASDAQ26,522.54+0.39%BTC$81,273.00+6.27%ETH$2,618.91+7.14%GOLD$4,415.90+0.37%OIL$95.47-1.81%
Smart Investors Daily
LY

NASDAQ · LYEL

Lyell Immunopharma, Inc.

Healthcare · Biotechnology

$11.01

Up+$0.21 (+1.94%)

Updated Sep 20, 2026, 6:37 PM

SID Score

2.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
708.04M
P/E ratio
-1.87
Dividend yield
0.00%
52-week range
$10.46 – $45.00
Volume
401.13K
Avg. volume
48.46K

Price performance

LYEL price history

1M range · 19 trading sessions · Daily adjusted prices

LYEL closed at $11.01 after 19 trading sessions, down 25.31% for the selected period.

Last close
$11.01
Period change
-25.31%
Period low
$10.78
Period high
$15.49
Daily close
View OHLC price history
LYEL OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 18, 2026$10.75$11.045$10.53$11.01401.13K
Sep 17, 2026$11.01$11.06$10.60$10.80133K
Sep 16, 2026$10.90$10.9799$10.46$10.775154.7K
Sep 15, 2026$11.29$11.29$10.55$10.91184.15K
Sep 14, 2026$11.97$12.385$11.24$11.33104.41K
Sep 11, 2026$12.41$13.00$11.70$11.96152.2K
Sep 10, 2026$12.70$12.71$12.04$12.20111.12K
Sep 9, 2026$13.52$13.82$12.71$12.88101.57K
Sep 8, 2026$14.12$14.13$13.37$13.5383K
Sep 4, 2026$14.29$14.68$13.92$14.3754.07K
Sep 3, 2026$15.11$15.14$14.19$14.3279.05K
Sep 2, 2026$14.49$14.97$14.25$14.95556.86K
Sep 1, 2026$14.14$14.835$14.00$14.52567.01K
Aug 31, 2026$14.51$14.71$14.14$14.3262.77K
Aug 28, 2026$14.56$14.78$14.06$14.5378.12K
Aug 27, 2026$14.67$15.02$14.33$14.6188.38K
Aug 26, 2026$15.34$15.4102$14.61$14.8087.78K
Aug 25, 2026$15.02$15.68$14.92$15.49103K
Aug 24, 2026$15.30$15.49$14.46$14.7473.24K

Latest LYEL news

The latest Smart Investors Daily articles mentioning LYEL.

Stock researchCompany · Overview

LYEL research

Overview

Company profile and research snapshot.

Company profile

Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$45.00
Implied upside
—
Analysts
—
LYEL recent ratings
DateFirmRatingTarget
Sep 11, 2026NeedhamBuy—
Aug 6, 2026StifelBuy—
Jul 22, 2026B. Riley SecuritiesBuy—
Jun 15, 2026CitizensMarket Outperform—
Jun 15, 2026NeedhamBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 14, 2026

Lyell Immunopharma To Participate in the Baird 2026 Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced that members of its senior management team will participate in the Baird 2026 Global Healthcare Conference on Tuesday, September 15, 2026, in New York with a fireside chat scheduled for 2:00 pm Eastern Time. A live webcast of the fire

Yahoo · Sep 10, 2026

Lyell Immunopharma Completes Manufacturing Transfer for LYL273 and Provides Updated Timeline on Phase 1/2 Trial in Metastatic Colorectal Cancer

Technology transfer to LyFE Manufacturing Center™ completed following FDA review of improved manufacturing process and updated analytical methodsDosing of additional patients with the new process at LyFE continues with the goal of determining the recommended Phase 2 dose and optimized safety management plan to support End-of-Phase 1 discussions with the FDAAdditional clinical data from the Phase 1/2 trial of LYL273 in patients with third- or later-line relapsed/refractory metastatic colorectal c

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By